XoMA 052, a potential disease-modifying anti-interleukin-1 beta (IL-1 beta) regulatory antibody, shows reductions in hs-cRP, HbA1c and FPG after subcutaneous injection in a randomized, blinded, placebo-controlled trial in subjects with type 2 diabetes mellitus

Despite the very promising characteristics of gevokizumab, important questions remain to be answered. One important question is what to expect from a combination of this agent with insulin and if there is a subset of patients that might respond more favorably to treatment. We also need to know at what stage in the natural history of T1DM could gevokizumab be most efficacious, as well as its potential effects on cardiovascular outcomes.

show abstract

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

Pafili

Παπάνας

Maltezos

2014

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

XoMA 052, a potential disease-modifying anti-interleukin-1 beta (IL-1 beta) regulatory antibody, shows reductions in hs-cRP, HbA1c and FPG after subcutaneous injection in a randomized, blinded, placebo-controlled trial in subjects with type 2 diabetes mellitus

Cited by 1 publication

References 0 publications

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

Contact Info

Product

Resources

About